REGULATORY

• Clinical Trial Matching Websites Do Not Violate Ad Regulations in PMD Act: MHLW
  April 10, 2025

• MHLW Sets Up Task Force to Brace for US Tariffs
  April 10, 2025

• Repeal of Off-Year Revision Means No Price Raise for Unprofitable Drugs: Minister
  April 10, 2025

• Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
  April 10, 2025

• Chuikyo OKs Discussion Timeline for FY2026 Reimbursement Reform
  April 10, 2025

• Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
  April 10, 2025

• Label Revisions Ordered for Xtandi, Paxlovid, and More Drugs
  April 9, 2025

• Revise Regulations of Clinical Trial Info in PMD Act: Patient Advocate to Diet
  April 9, 2025

• FPMAJ Renews Call for Scrapping Off-Year Drug Price Revision: Diet Hearing
  April 9, 2025

• Japan Economic Minister Akazawa to Lead Tariff Talks with US
  April 9, 2025

• PMDA Announces Guidance on “Competing Products” in Regulatory Review
  April 8, 2025

• MHLW Now Soliciting Bids for FY2025 Budget Projects to Fight Drug Lag/Loss
  April 8, 2025

• Ishiba, Trump Agree to Appoint Ministers for Tariffs Talks
  April 8, 2025

• Public-Private Council Will Meet This Summer: Japan PM
  April 8, 2025

• Ishin Prods Govt to End Fee Incentives for Generic Use, Minister Says Topic Up for Chuikyo Discussions
  April 7, 2025

• Diet Begins Deliberations on Amendment of PMD Act, Bill to Repeal Off-Year Scheme
  April 7, 2025

• Shingles Shots Added to NIP, HPV Catch-Up Program Extended: MHLW
  April 7, 2025

• LDP’s New Fiscal Reform HQ to Release Draft Report by Late May
  April 4, 2025

• 3-Party Talks Fail to Reach Specifics on OTC-Like Drugs
  April 4, 2025

• Japan Mulls Amendment of GCP Ordinance, Making Single IRBs a Rule
  April 3, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• 36
• 37
• …
• Next ›
• 最終 »